Pitt Pediatrics and UPMC Children’s Hospital of Pittsburgh excitedly congratulates Silva Arslanian, MD, for being awarded the American Diabetes Association’s (ADA) 2023 Outstanding Achievement in Clinical Diabetes Research Award. Arslanian is the Richard L. Day Professor of Pediatrics and Clinical and Translational Science, the Director of the Pediatric Clinical and Translational Research Center (PCTRC), and the Scientific Director of the Center for Pediatric Research in Obesity and Metabolism (CPROM). 
Arslanian was presented the award at the ADA’s Annual Scientific meeting on June 26th in San Diego, California. Robert Gabay, MD, PhD, FACP, Chief Scientific and Medical Officer of the ADA presented the award (photo below). First announced in March of this year, the ADA’s Clinical Diabetes Research Award recognizes Arslanian’s exceptional contributions towards patient-oriented clinical research that have had a significant impact on diabetes prevention and treatment.
The ADA specifically credits her work as considerably expanding knowledge of the “pathophysiological mechanisms of youth-onset type 2 diabetes, the rapid deterioration in β-cell function, and the impaired incretin effect through detailed investigations of insulin sensitivity and β-cell function during childhood growth and development in health and disease.”
This award is highly competitive and is rarely given to pediatricians. Arslanian is the first woman who has received it.
Arslanian’s research has recently been published in The New England Journal of Medicine on the role of semiglutinide in adolescents and on clinical guidelines for treating obesity in children.
Follow Pitt Pediatrics on Twitter and Instagram for future updates on Arslanian’s work and research within CPROM.